Erratum: Correction: Effectiveness of plasma lyso-Gb3 as a biomarker for selecting high-risk patients with Fabry disease from multispecialty clinics for genetic analysis (Genetics in medicine : official journal of the American College of Medical Genetics (2019) 21 1 (44-52))

Hiroki Maruyama, Kaori Miyata, Mariko Mikame, Atsumi Taguchi, Chu Guili, Masaru Shimura, Kei Murayama, Takeshi Inoue, Saori Yamamoto, Koichiro Sugimura, Koichi Tamita, Toshihiro Kawasaki, Jun Kajihara, Akifumi Onishi, Hitoshi Sugiyama, Teiko Sakai, Ichijiro Murata, Takamasa Oda, Shigeru Toyoda, Kenichiro HanawaTakeo Fujimura, Shigehisa Ura, Mimiko Matsumura, Hideki Takano, Satoshi Yamashita, Gaku Matsukura, Ryushi Tazawa, Tsuyoshi Shiga, Mio Ebato, Hiroshi Satoh, Satoshi Ishii

Research output: Contribution to journalComment/debatepeer-review

1 Citation (Scopus)

Abstract

The PDF and HTML versions of the article have been updated to include the Creative Commons Attribution 4.0 International License information.

Original languageEnglish
Pages (from-to)1900
Number of pages1
JournalGenetics in medicine : official journal of the American College of Medical Genetics
Volume21
Issue number8
DOIs
Publication statusPublished - 2019 Aug 1

ASJC Scopus subject areas

  • Genetics(clinical)

Fingerprint Dive into the research topics of 'Erratum: Correction: Effectiveness of plasma lyso-Gb3 as a biomarker for selecting high-risk patients with Fabry disease from multispecialty clinics for genetic analysis (Genetics in medicine : official journal of the American College of Medical Genetics (2019) 21 1 (44-52))'. Together they form a unique fingerprint.

Cite this